FDA Approves Welireg With Pembrolizumab for Renal Cell Carcinoma

THURSDAY, June 18, 2026-- The U.S. Food and Drug Administration has approved Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma...